With the increasing use of extracorporeal membrane oxygenation in children come increasing publications concerning pediatric ECMO. In 2016 important work was done in identifying modifiable risk-factors and possible predictors of mortality in cardiac and respiratory ECMO and risk-estimation scores have been developed for respiratory ECMO patients. Also, increasing important experience is published in the areas of neurodevelopmental follow-up of ECMO survivors. The most relevant publications of 2016 are summarized in this review.
Introduction
Extracorporeal Membrane Oxygenation (ECMO), also known as Extracorporeal Life Support (ECLS) is well established for cardiorespiratory failure. The use of ECLS is increasing with currently more than 55.000 pediatric patients since 1990. 1 This increasing experience is reflected in the literature with increasing publications concerning pediatric ECMO. Because of the large amount of publications, it can be difficult to keep up with all new literature regarding all aspects of our professional interests and responsibilities, not only ECMO. Therefore, the aim of this review was to give an overview of the most relevant publications regarding pediatric ECMO from 2016.
Most publications concern pediatric cardiac ECMO with more than 10 retrospective single-center studies and also large retrospective data-base studies. Three large United States national and international databases are regularly queried for these larger outcome studies: The Extracorporeal Life Support Organization (ELSO), The United States Pediatric Health Information System (PHIS), and the US Kids Inpatient Database (KID). Survival of ECMO is not the only goal anymore and there is growing interest in neurodevelopment of our ECMO patients. This is reflected in the number of publications of follow-up studies. Anticoagulation remains one of the more difficult aspects of ECMO and is discussed in several published studies. Importantly, in 2016 risk-estimation scores have been developed and published, all concerning pediatric respiratory ECMO. Studies concerning pharmacology are still lacking with only few publications in 2016. The care of children on ECMO is a complicated task with many different aspects. Not all 
Discussion

ANTICOAGULATION:
Anticoagulation remains a 'hot topic' as caregivers are trying to find ways to perfect anticoagulation strategies. Heparin is most often used. But still thrombotic and bleeding complications remain high in the ECMO population and remain risk factors for mortality. Stansfield et al, performed a retrospective review of the effect of implementing routine antithrombin (AT) replacement in 162 infants undergoing respiratory ECMO. The authors reported fewer thrombotic complications, similar haemorrhagic complications, and significantly less use of blood products. 2 A retrospective multicenter cohort study of the PHIS database, by Wong et al, showed that AT use has dramatically increased over the 10-year study period from 2.4 to 52% of ECMO patients.
PK alterations that affect drug disposition which can cause either therapeutic failures or increased drug toxicity. Himebauch et al, published an insightful review article in 2016 in which the authors describe the PK changes during ECMO with associated therapeutic implications of various classes of drugs commonly used for pediatric patients on ECMO (sedatives, analgesics, antimicrobials, and cardiovascular drugs). 4 A retrospective observational study by Anton-Martin et al, demonstrated that providing comfort to pediatric ECMO patients with younger age, pediatric respiratory failure, thoracic cannulation and prolonged use of muscle relaxants can be more challenging. 5 Prospective studies are required to address risk factors for increased medication requirements and optimization of analgesia and sedation management in children on ECMO.
MONITORING DURING ECMO
Publications on monitoring during ECMO mainly focus on the neurological effects of ECMO in an attempt to identify variables that would be predictive of cerebrovascular complications in the near and more distant future of ECMO patients. Zamora et al, describe a novel transcranial sonography technique which can be performed at the bed-side in neonates with a fontanelle (resistive index variability) which was associated with greater risk of cerebrovascular complications. 6 Another technique, frequency-domain near-infrared spectroscopy (NIRS), can be used outside the neonatal population. Tian et al, showed that frequency-domain NIRS can detect loss or decreased density of brain matter which could potentially be helpful as a bed-side screening tool for the detection of intracranial complications during ECMO therapy.
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RISK FACTORS AND OUTCOMES
One of the main difficulties in caring for ECMO patients is deciding which patient may benefit from ECMO at which point in their disease progression. To that end, a lot of work is continuingly being done to identify possible risk factors that may influence outcomes. Topics include pre-ECMO risk factors such as diagnosis and severity of illness, timing of ECMO initiation, ECMO management, ECMO complications such as infections, comorbidities such as renal injury, and organizational influences such as hospital size. Identification of modifiable risk factors may lead to improved candidate selection and ECMO management in this high-risk population.
Anton-Martin et al, showed in a retrospective single center review of 20 years and 491 pediatric ECMO patients, that 24% of their patients were underweight which was independently associated with increased mortality with an odds ratio (OR) of 2. 8 In a retrospective review of the PHIS database, the use of inhaled nitric oxide (iNO) during ECMO treatment was evaluated. 9 The authors found that iNO was used in 3629 of 6419 pediatric ECMO patients, that only 22% of those receiving iNO had pulmonary hypertension, that the use of iNO was associated with longer ECMO duration and LOS, that iNO use was very expensive, and that the use of iNO was not associated with a survival benefit. This large exploratory observational analysis calls into question the benefits of iNO-use during ECMO. Two studies have specifically looked at the influence of renal injury or failure. 10, 11 Preventing acute renal failure (ARF) during, or preferably before, pediatric ECMO is of interest as this could possibly impact on the negative effect of ARF on clinical outcomes. In a retrospective study in 42 children during ECMO after cardiac surgery (median age 13 months), the incidence of ARF was 41%. With multiple regression analysis, maximum free plasma haemoglobin and lactate pre-ECMO were risk factors for ARF. The authors found a significant difference in survival between ARF patients and non-ARF patients (6% versus 84% respectively). 10 The second study, a multicenter retrospective observational cohort study of 822 ECMO patients (56% respiratory ECMO) identified acute kidney injury (AKI) in 60-74% depending on which criteria they used. 11 In the majority of patients AKI was present at initiation of ECMO support and was associated with longer duration of ECMO support and increased risk of mortality.
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HOSPITAL VOLUMES AND STRUCTURE
The organization of a hospital and ECMO center might influence performance and outcomes as it is a commonly held notion that better health care outcomes are associated with hospitals and clinicians that carry large volumes of activity. 12 Kirkland et al, performed a retrospective cohort study of respiratory ECMO, using the PHIS database and divided centers in low volume (<20 ECMO's per year), medium volume (20-49 ECMO's per year), and large volume (>50 ECMO's per year). 13 The authors found that ventricular haemorrhage and ARF were more common in low volume centers and were associated with hospital mortality in neonates. Mortality in congenital diaphragmatic hernia patients was significantly lower in high-volume centers. The authors suggest that earlier initiation of ECMO prior to development of multi-organ failure, careful attention for intraventricular hemorrhage, and attention for bronchoscopy might improve outcomes.
13
In contrast, another retrospective PHIS analysis focussed on the volume-outcome relationship in children receiving ECMO for heart operations and found that high-volume centers were not associated with improved survival.
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CARDIAC ECMO
Several studies specifically address factors associated with mortality among ECMO for cardiac indications. Ford et al, performed a retrospective cohort study of 4471 neonates with congenital and acquired heart disease utilizing the ELSO registry.
14 Approximately half of patients had biventricular circulation and one-third were extracorporeal cardiopulmonary resuscitation (ECPR) patients. Median ECMO duration was 111 hours, overall hospital mortality was 59%, and factors associated with mortality were lower body weight, single ventricle physiology, pre-ECMO acidosis, and longer time between intubation and ECMO initiation. The majority of survivors separated from ECMO within 8 days. ECMO duration was longer in nonsurvivors. In neonates requiring ECMO following cardiac surgery, the early identification of residual lesions may improve survival as shown in a retrospective study of 84 neonates. 15 In this study, increased mortality was associated with prematurity (OR 2.3), pre-ECMO pH < 7.17 (OR 2), inotropes during ECMO (OR 4), ECMO duration > 168 hours (OR 2), unresolved lactic acidosis (OR 2.8), and time to diagnosis of residual lesions (1 vs 2 days, p = 0.02). Residual lesions can be identified and, sometimes, addressed via cardiac catheterization. Abraham et al, showed that survival was significantly better with transcatheter interventions compared with no intervention in patients with congenital heart disease. 16 Major catheter complications, requiring surgical intervention, occurred in 7% of catheterizations, no complications occurred during transport, and survival improved if catheterization was done early in the ECMO course (1.6 vs 3.5 days).
Timing initiation of ECMO after cardiac surgery is difficult and no strict criteria exist that help decide when a specific patient would benefit from escalation of therapy to ECMO. In a retrospective PHIS database study of pediatric patients receiving ECMO after heart surgery, increasing duration of time from surgery to ECMO initiation was associated with longer ventilation duration, longer ECMO duration, and longer hospital LOS, but not with increased mortality.
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A retrospective analysis of the KID database of 701 single-ventricle (SV) patients supported with ECMO was published by Misfeldt et al. 18 ECMO support had significantly increased over the years but was still reasonably uncommon. Mortality was 57% and ARF was found to be an independent risk factor for mortality after multivariate analysis (OR 3.3). In SV patients palliated via the hybrid procedure, incidence of ECMO was found to be significantly lower than following the Norwood procedure in a retrospective single-center review of 181 hybrid procedures, but mortality was higher. 19 In another retrospective study of 93 infants post cardiac surgery (median age 7 days), a partial pressure of oxygen above 193 mmHg was an independent risk factor for mortality. 20 The authors speculate that hyperoxia might be harmful because of the generation of reactive oxygen species leading to increased oxidative stress and cellular damage and an exaggerated inflammatory and thrombotic cascade. They suggest future prospective studies are necessary to investigate the effect of hyperoxia while on ECMO, but also that a change of practice in management of these patients in many centers might be prudent. 20 Cardiac ECMO patients are typically supported with VA-ECMO, but VV-ECMO in single-ventricle (SV) patients is also possible, especially in ARDS patients when conventional therapy fails. Special thought is necessary given the unique SV physiology, including cannulation, hemorrhagic, thrombotic, circuit flow, and lung rest considerations. Aydin et al performed a retrospective review of the ELSO database and identified 89 SV patients supported with VV ECMO. 21 Sixty-one percent had shunt physiology, 25% had cavopulmonary connections, and 14% were supported prior to surgery. Indications for ECMO were mainly respiratory failure (63%) or cardiac failure (32%). Survival to discharge was 48% and was associated with mean airway pressure pre-ECMO and renal injury. The authors conclude that patients with SV anatomy in respiratory failure may be treated successfully with VV-ECMO, with survival comparable to those treated for cardiac failure using VA-ECMO.
Two studies reported on ECPR. op CPR was 77 minutes, median duration of ECMO was 5 days, and hospital mortality was 84%, which is higher than most other reports. 22 Survivors tended to have lower lactate, higher pH and shorter duration of resuscitation, although all not statistically significant. Erek et al, retrospectively studied their 25 ECPR patients after cardiac surgery. 23 Four percent of their cardiac operations required ECPR postoperatively. In 88% the cardiac arrest occurred in the first 24 hours after surgery. Median support was 3 days and 44% survived beyond 7 days after decannulation. Survival to hospital discharge was 20%. Duration of CPR and biventricular physiology were significantly and independently associated with survival.
MYOCARDITIS
Two studies were published regarding ECMO in fulminant myocarditis. 24, 25 The first is a review of 8 cases of fulminant myocarditis requiring ECMO in children with a median age of 8 years. 24 Four patients survived peripheral VA-ECMO, two were switched to VAD of whom one survived. Total survival to discharge was 75%. Longer duration of ECMO support was associated with decreased survival. The second study is a retrospective review of 18 cases of fulminant myocarditis of which 16 (89%) had an arrhythmia at presentation. 25 Seven children were supported with ECMO, and all survived. Median time to from admission to cannulation was 4 hours and median support time was 98 hours. At 6 month follow-up all ECMO children had recovered fully.
DEVELOPMENT OF RISK ESTIMATE SCORES
In 2016 three pediatric risk estimate scores were published for respiratory ECMO patients 26 -28 and a fourth was published in January 2017. 29 Previously no risk estimate scores were available for children on ECMO. Current indications for ECMO in pediatric respiratory failure include acute, potentially reversible, respiratory failure not responding to conventional ventilator and medical therapies. The optimal timing of intervention with ECMO remains a question and creating objective tools to predict likelihood of success of ECMO support could certainly benefit caregivers.
Barbaro et al., developed two risk estimate scores, one for neonates and one for pediatric patients. 26, 27 The authors used the ELSO registry to identify candidate variables, to develop the score, and also to validate the score. For pediatric patients the ped-RESCUERS score was developed (www.ped-rescuers.com) and for neonates the neo-RESCUERS score (www.neo-rescuers .com) which both can be found online. Both scores provide a novel measure of pre-ECMO mortality risk and are a promising step towards creating a pre-ECMO mortality risk estimation tool. At the moment these scores cannot be used as selection tools. They cannot predict if an individual patient will benefit from ECMO support or not. However, they have three possible important applications. The first is to provide risk-adjusted internal and external benchmarking of ECMO performance quality. Second, these severity of illness scores can help enhance observational research. And, third, these scores can help physicians anticipate the risk of mortality prior to ECMO which can be helpful in informing family. 26, 27 Maul et al, also used the ELSO registry to develop an estimation tool for neonatal respiratory ECMO patients with the intention of developing a means of meaningful comparisons amongst patient populations. 28 They only included VA-ECMO patients, in contrast to the previous scores that also included VV-ECMO patients. Based on 7 pre-ECMO variables, the authors developed the PIPER score (Pittsburgh Index for Pre-Ecmo Risk). The PIPER+ score also includes complications during ECMO and duration of ECMO (www .elso.org//resources/PIPERscore.aspx).
The fourth score that was developed, also used the ELSO registry data from > 4000 children with respiratory ECMO but then validated their score using over 2000 patients from the PHIS dataset. 29 The authors included 14 variables to develop the P-PREP score (www.picuscientist.org/pprep/).
LONG TERM SURVIVAL AND NEURODEVELOPMENTAL FOLLOW-UP
Short term survival rates are well known and vary depending on diagnosis, severity of illness, type of support, duration of support, comorbidities, complications, etcetera. More and more attention is being given to the long-term effect of ECMO support with several well developed follow-up programs.
A retrospective review of 41 neonates after VA-or VV-ECMO, who were evaluated with MRI, identified an abnormal cerebral metabolic profile suggestive of an inflammatory process and/or vasogenic edema. 30 The authors hypothesize that these subtle differences in the brains of ECMO survivors might play a role in later neurodevelopmental impairments. A prospective observational study in 135 ECMO survivors focused on quality of life (QOL), which was lower than normal. 31 Survivors with severe neurologic or behavioral comorbidity were excluded, but the rest reported feeling satisfied with their motor-and social competence, despite impaired QOL and motor problems. The authors conclude that clinicians should be aware that these patients may 'overrate' their actual motor performance and strict monitoring of this motor performance is important to enable timely intervention. A Dutch study group performed neuropsychological follow-up of neonatal ECMO survivors at 2, 5, and 8 years. 32 School problems were found to be related to diminished selective attention and not to intelligence-testing as mean IQ was normal, despite academic problems. The same group also studied 13 ECMO survivors who had reached the age of 17 or 18 years and found that adolescent performance was significantly lower than the norm on verbal memory, visual-spatial memory, and working memory. 33 The authors suggest future research should focus on longitudinal outcome of specific neuropsychological skills, identifying risk factors of neuropsychological dysfunction, evaluating to what extent 'severity of illness' is responsible for acquired brain injury, and the effects of timely cognitive rehabilitation. These follow-up studies indicate the importance of well set-up programs to help identify neurodevelopmental problems as soon as possible to allow for timely intervention. Whether intervention can improve outcomes needs to be investigated in future prospective studies.
. 
Conclusion
In conclusion, ECMO is considered a standard therapeutic option for children who are refractory to conventional medical interventions. However, deciding which child will benefit from ECMO remains difficult and therefore subject of ongoing research. ECMO is not a solution to all problems, and we need to try and find ways to better predict outcomes and limit complications of therapy. In 2016 a few very important steps have been made with the development of risk estimation scores. 26 -29 Further research can focus on external validation of these scores and identifying other modifiable risk factors that could help improve prognostication. Another very important focus of current, and future research, is neurodevelopmental follow-up as ECMO patients have been found to have delayed development in many areas. Survivors of ECMO report an adequate QOL despite physical and mental limitations. Hopefully, more centers will develop follow-up programs and share their results with the ECMO community.
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